HC Wainwright Reiterates $5.00 Price Target for Verastem Inc (VSTM)
Several other research analysts have also recently commented on the company. Cantor Fitzgerald reaffirmed a buy rating and issued a $3.00 target price on shares of Verastem in a research report on Tuesday, August 9th. Zacks Investment Research upgraded Verastem from a hold rating to a buy rating and set a $1.50 price objective for the company in a research note on Thursday, August 11th. Finally, Jefferies Group reiterated a hold rating and set a $1.50 price objective on shares of Verastem in a research note on Friday, August 5th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $2.75.
Shares of Verastem (NASDAQ:VSTM) opened at 1.49 on Tuesday. Verastem has a one year low of $1.05 and a one year high of $2.43. The firm has a 50-day moving average of $1.36 and a 200-day moving average of $1.41. The firm’s market capitalization is $55.12 million.
Verastem (NASDAQ:VSTM) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.06. On average, equities analysts predict that Verastem will post ($0.94) earnings per share for the current fiscal year.
Several hedge funds have recently made changes to their positions in VSTM. Paloma Partners Management Co acquired a new stake in shares of Verastem during the second quarter worth $153,000. BlackRock Advisors LLC raised its stake in shares of Verastem by 3.9% in the second quarter. BlackRock Advisors LLC now owns 119,056 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 4,418 shares during the period. GSA Capital Partners LLP acquired a new stake in shares of Verastem during the second quarter worth $179,000. Granite Point Capital Management L.P. acquired a new stake in shares of Verastem during the second quarter worth $179,000. Finally, Emerald Acquisition Ltd. acquired a new stake in shares of Verastem during the second quarter worth $179,000.
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc and related companies with MarketBeat.com's FREE daily email newsletter.